Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:NOG NYSEAMERICAN:SYN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeNOGNorthern Oil and Gas$21.00-4.0%$25.45$20.18▼$32.62$2.38B0.682.67 million shs2.02 million shsSYNSynthetic Biologics$0.00$0.97▼$4.56$16.16M1.38197,338 shs57,700 shsThe Rise of the RobotsRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and industrial operations. This report explores the rise of “Physical AI,” highlights four key ways investors can gain exposure to the robotics revolution, and profiles seven leading companies positioned to benefit from the growing demand for intelligent automation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceNOGNorthern Oil and Gas-1.26%+0.75%-17.88%-24.04%-22.42%SYNSynthetic Biologics0.00%0.00%0.00%0.00%0.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeNOGNorthern Oil and Gas$21.00-4.0%$25.45$20.18▼$32.62$2.38B0.682.67 million shs2.02 million shsSYNSynthetic Biologics$0.00$0.97▼$4.56$16.16M1.38197,338 shs57,700 shsThe Rise of the RobotsRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and industrial operations. This report explores the rise of “Physical AI,” highlights four key ways investors can gain exposure to the robotics revolution, and profiles seven leading companies positioned to benefit from the growing demand for intelligent automation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceNOGNorthern Oil and Gas-1.26%+0.75%-17.88%-24.04%-22.42%SYNSynthetic Biologics0.00%0.00%0.00%0.00%0.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceNOGNorthern Oil and Gas 2.20Hold$33.0057.14% UpsideSYNSynthetic Biologics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest SYN, DELT, SENX, and NOG Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/22/2026NOGNorthern Oil and Gas Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingUnderweight$28.00 ➝ $29.005/21/2026NOGNorthern Oil and Gas Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Outperform$37.00 ➝ $35.005/20/2026NOGNorthern Oil and Gas Johnson RiceSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeAccumulate ➝ Hold$36.005/4/2026NOGNorthern Oil and Gas Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D+)4/21/2026NOGNorthern Oil and Gas Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C-)4/14/2026NOGNorthern Oil and Gas CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$39.00 ➝ $36.004/8/2026NOGNorthern Oil and Gas Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetSector Perform$30.00 ➝ $35.003/31/2026NOGNorthern Oil and Gas CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$34.00 ➝ $39.003/27/2026NOGNorthern Oil and Gas Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingUnderweight3/24/2026NOGNorthern Oil and Gas Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$27.00 ➝ $32.00(Data available from 6/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookNOGNorthern Oil and Gas$2.06B1.11$12.43 per share1.69$21.79 per share0.96SYNSynthetic BiologicsN/AN/AN/AN/A$4.95 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateNOGNorthern Oil and Gas$38.76M-$6.37N/A5.38N/A-33.17%18.43%7.14%7/30/2026 (Estimated)SYNSynthetic Biologics-$14.27M-$1.21N/AN/AN/AN/A-26.14%-22.74%N/ALatest SYN, DELT, SENX, and NOG EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/28/2026Q1 2026NOGNorthern Oil and Gas$0.71$0.74+$0.03-$5.31$511.38 million$5.03 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthNOGNorthern Oil and Gas$1.808.57%N/AN/A 4 YearsSYNSynthetic BiologicsN/AN/AN/AN/AN/ALatest SYN, DELT, SENX, and NOG DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/13/2026NOGNorthern Oil and Gasquarterly$0.457.71%6/29/20266/29/20267/31/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioNOGNorthern Oil and Gas1.430.530.53SYNSynthetic BiologicsN/A4.144.14Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipNOGNorthern Oil and Gas98.80%SYNSynthetic Biologics74.38%Insider OwnershipCompanyInsider OwnershipNOGNorthern Oil and Gas2.80%SYNSynthetic Biologics2.15%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableNOGNorthern Oil and Gas30108.78 million102.15 millionOptionableSYNSynthetic Biologics1615.84 million15.50 millionNot OptionableSYN, DELT, SENX, and NOG HeadlinesRecent News About These CompaniesComputational design drives new generation of synthetic promotersMarch 27, 2026 | drugtargetreview.comDGene Synthesis Market Comprehensive Industry Analysis, Trends, and Future OutlookFebruary 25, 2026 | pharmiweb.comP6 ways biologics is advancing in spineFebruary 19, 2026 | beckersspine.comBStopping Biologics Before Surgery May Raise Flare Risk in RAJanuary 27, 2026 | rheumatologyadvisor.comRStudy Shows NanoFuse(R) Superiority: Why Bioactive Glass-DBM Composites Outperform DBM and Bioactive Glass AloneJanuary 26, 2026 | marketwatch.comMTF Biologics and Kolosis BIO Launch New Solution for Orthopedic and Spinal Surgeries: Summit Matrix™January 15, 2026 | uk.finance.yahoo.comMTF Biologics and Kolosis BIO Launch New Solution for Orthopedic and Spinal Surgeries: Summit Matrix(TM)January 15, 2026 | marketwatch.comAsimov and AGC Biologics Team Up to Provide a Cost-Effective, Simplified, and Secure Manufacturing Approach for Viral Vector ProductionJanuary 13, 2026 | pharmiweb.comP4 orthobiologics updatesDecember 18, 2025 | beckersspine.comBExposure to Some DMARDs in Fathers-to-Be Tied to Birth RisksDecember 2, 2025 | medscape.comMRelapse in Juvenile Idiopathic Arthritis After Stopping DMARDs: Key Factors FoundDecember 1, 2025 | medscape.comMConstructive Bio and RxCelerate partner to develop biologic therapeutic candidatesNovember 19, 2025 | businessweekly.co.ukBRA Onset Age Doesn’t Affect Non-TNF Agents’ Infection RiskOctober 29, 2025 | medscape.comMAurora Spine Launches New Biologics PortfolioOctober 28, 2025 | markets.businessinsider.comWound Care Biologics Market Size Worth USD 11.22 Billion by 2034October 27, 2025 | finance.yahoo.comStudy assesses SI joint outcomes between surgeons, pain physiciansOctober 21, 2025 | beckersspine.comBActive Pharmaceutical Ingredients (API) Market worth $198.39 billion by 2030 with 6.6% CAGR | MarketsandMarkets™October 15, 2025 | finance.yahoo.comRheumatoid Arthritis Linked to Elevated Pneumonia Risk, Especially in Seropositive DiseaseOctober 1, 2025 | ajmc.comAProtein Expression Market to Hit USD 6.60 Billion by 2032 on Rising Biologics and Personalized Medicine Demand | S&S InsiderSeptember 26, 2025 | finance.yahoo.comFrom Synthetic Identities to Synthetic Receipts: The New Frontier of FraudJuly 17, 2025 | securityinfowatch.comSNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSpaceX Gets the Attention, But These 4 Stocks Could Get the ReturnsBy Bridget Bennett | May 25, 2026Before the Moon Base Gets Built, These 4 Companies WinBy Thomas Hughes | May 11, 2026IonQ Just Posted a Breakout Quarter—But 1 Problem RemainsBy Nathan Reiff | May 7, 2026Amylyx Stock: Why the Full Pipeline Story MattersBy Chris Markoch | May 24, 2026Shares Fall, Targets Rise—Markets and Analysts Diverge on SynopsysBy Leo Miller | May 29, 2026SYN, DELT, SENX, and NOG Company DescriptionsNorthern Oil and Gas NYSE:NOG$21.00 -0.88 (-4.02%) Closing price 03:59 PM EasternExtended Trading$21.08 +0.07 (+0.36%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Northern Oil and Gas, Inc., an independent energy company, engages in the acquisition, exploration, exploitation, development, and production of crude oil and natural gas properties in the United States. It primarily holds interests in the Williston Basin, the Appalachian Basin, and the Permian Basin in the United States. The company is based in Minnetonka, Minnesota.Synthetic Biologics NYSEAMERICAN:SYNSynthetic Biologics, Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics; SYN-005 for the prevention and treatment of pertussis; and VCN-11 to treat cancer. It has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Synthetic Biologics, Inc. is headquartered in Rockville, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below Five Below Down 12% Post Earnings—Is the Selloff Overdone? Buy the Dip? Broadcom's AI Moat Is Wider Than Ever The Market Has Ollie’s Bargain Outlet Completely Wrong Broadcom's Whiplash: Shares Tank After Pre-Earnings Surge Navitas: NVIDIA’s AI Power Broker? Macy's Delivers Strong Q1, Raises Outlook, but Wall Street Remains Cautious NVIDIA's New Power Play: Why Fluence Is Surging Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
